(NASDAQ: EDIT) Editas Medicine's forecast annual revenue growth rate of -20.73% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.85%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.4%.
Editas Medicine's revenue in 2025 is $35,836,000.On average, 4 Wall Street analysts forecast EDIT's revenue for 2025 to be $940,513,971, with the lowest EDIT revenue forecast at $641,240,500, and the highest EDIT revenue forecast at $1,729,507,667. On average, 4 Wall Street analysts forecast EDIT's revenue for 2026 to be $1,534,038,141, with the lowest EDIT revenue forecast at $334,851,436, and the highest EDIT revenue forecast at $3,432,227,219.
In 2027, EDIT is forecast to generate $987,811,736 in revenue, with the lowest revenue forecast at $987,811,736 and the highest revenue forecast at $987,811,736.